Approximately 40% of gliomas exhibit MGMT methylation, leading to decreased MGMT expression i.e., decreased DNA repair and therefore to an enhanced sensitivity to TMZ, which significantly prolongs survival compared to patients without the methylation of this site [8]. This evidence concerns the gene MGMT and central nervous system cancer.